There are two trials that I think are probably the most excited about. One of them is called the PEAK trial, and it was a ...

GISTs are a rare type of cancer that develops in the digestive tract’s connective tissue, specifically from cells that help regulate muscle contractions. GISTs are primarily driven by genetic ...

NEW YORK, March 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced breakthrough preclinical findings demonstrating the ...

GISTs originate from interstitial cells of Cajal and are staged by size, location, mitotic rate, and genetic mutations, influencing treatment strategies. Diagnosis involves imaging, endoscopy, biopsy, ...

Please provide your email address to receive an email when new articles are posted on . Imatinib interruption resulted in shorter median OS. Interruption also appeared linked to rapid progression and ...

GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK ...

Stomach cancer—or gastric cancer—occurs when cells in the lining of the stomach wall mutate and grow uncontrollably. The stomach wall has five layers, and different types of stomach cancer are often ...

New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...